On Echemi
Xiuzheng Pharmaceutical Group Co., Ltd
Favorite Supplier
272 people visit



No. 36, Xiuxian Road, Tonghua City, Jilin Province






Product List
Product Name CAS No. Grade/Content Operate

1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid

112811-59-3 Inquiry

Choline bitartrate

87-67-2 Inquiry


3493-12-7 Inquiry

Econazole nitrate

68797-31-9 Inquiry

Gatifloxacin sesquihydrate

180200-66-2 Inquiry


138402-11-6 Inquiry

Itopride hydrochloride

122892-31-3 Inquiry


63-68-3 Inquiry


3731-59-7 Inquiry

Moroxydine hydrochloride

3160-91-6 Inquiry
Company Profile
Xiu Laigui Group was founded in May 1995 by Chairman Xiu Laigui. It is a large-scale modern private pharmaceutical enterprise integrating scientific research, production, marketing, drug chain management, and standard cultivation of Chinese medicinal materials for patent medicine, chemical pharmacy, and biopharmaceuticals. The main pharmaceutical industry has also entered the health industry, tourism, and real estate industry to implement diversified development. While based in the country, it faces the world and develops the international market. By the end of 2016, the group had 127 subsidiaries with more than 100,000 employees. It has 24 dosage forms, more than 2,000 varieties of medicines and health products. Through secondary development, more than a dozen major varieties have been cultivated, including Fei Ning, Xiao Mi Suppository, Liuwei Dihuang, Jingyao Kang, Qi Qi and Nourishing Blood; the use of new preparation technology to develop Sidashu pellets and dispersible tablets has ensured the correction in the country. The position of the stomach medicine market. The amendment has a domestic scientific research system integrating scientific and technological management, innovative drug research, and the transformation of new technological achievements. There are more than 300 Chinese technical experts, more than 700 authorized patents, and 7 national scientific and technological progress awards. There are a nationally recognized enterprise technology center, a national engineering laboratory for quality control technology of traditional Chinese medicine, a post-doctoral scientific research station, and a key laboratory of key engineering technology for traditional Chinese medicine standardization. The Group's Science and Technology Innovation Center has six research institutes under its control, including the Beijing Huaxian New Drug Research Institute, Huaxiu Biomedicine (Hangzhou) Research Institute, and Beijing Medicinal Diet Research Institute. The group invests about 1 billion yuan in scientific research funding each year. Recombinant urate oxidase for injection is about to be put into production for the first-class national biologic drug for the treatment of tumor lysis syndrome. It is the second company in the world to produce this product after Sanofi. Launched the international cooperation development platform of genetic recombination series of hypoglycemic drugs, and jointly developed a series of hypoglycemic genetic engineering drugs such as insulin aspart and insulin detemir with India, and implemented the development of large-scale medicinal and edible fungi industrialization technology. On July 24, 2016, the China Pharmaceutical Industry Information Center hosted and hosted the 33rd National Pharmaceutical Industry Information Annual Conference and the 2015 China Pharmaceutical Industry Top 100 List released. Guangzhou Pharmaceutical ranked third afterwards; it was ranked 53 in the 2016 Top 500 Chinese Private Enterprises List sponsored by the All-China Federation of Industry and Commerce on August 25, 2016 and supported by the Ministry of Industry and Information Technology and the State Administration for Industry and Commerce. Ranked 29th in the 2016 Top 500 Chinese Private Enterprises Manufacturing List; ranked 252th in the 2015 Top 500 Chinese Enterprises List of the China Enterprise Confederation and Entrepreneurs Association.
Send an inquiry
Product Name:
Send Message